CClinicalTrials.gg
TerminatedNCT04930705Updated Oct 7, 2022

Study To Assess The Safety And Efficacy Of The Tempsure Flexsure Applicators For Abdominal Wrinkles

An interventional study of Treatment with TempSure Applicator in Wrinkle, sponsored by Cynosure, Inc.. Terminated at 1 site in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2022-10-07.

Sponsored by Cynosure, Inc. · Not applicable, Interventional, and Treatment

Why this study was terminated
This study was terminated because of a business decision.

From the registry’s dates

  • Primary completion was May 2022, 4 years 4 months ago, and no results have been posted to the registry.
Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

Subjects will be enrolled at 1 study center. Subjects may receive 5 treatments with the TempSure® device on the abdomen for wrinkles.

02

Conditions studied

  • Wrinkle
03

In context

Lead sponsor

Cynosure, Inc. is the lead sponsor of 52 studies on the registry; 2 are open to participants now.

Of its 21 completed or terminated interventional studies of FDA-regulated products, 16 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • A healthy, non-smoking male or female between the age of 18 - 55 years old.
  • Willing to receive treatments with the TempSure® device.
  • Understand and accept obligation not to receive any other procedures on the treatment and control area throughout the length of the study.
  • Understands and accepts the obligation and is logistically able to be present for all visits.
  • Is willing to comply with all requirements of the study and sign the informed consent document.

Exclusion criteria

Exclusion Criteria:

  • Is pregnant or of child bearing potential and not using medically effective birth control, or has been pregnant in the last 3 months, currently breast feeding or planning a pregnancy during the study.
  • The subject is currently enrolled in an investigational drug or device trial or has received an investigational drug or been treated with an investigational device within in the area to be treated 6 months prior to entering this study.
  • The subject has a cut, wound, or infected skin on the area to be treated.
  • The subject is on local, oral, or systemic anesthetic agents.
  • The subject has nerve insensitivity to heat in the treatment area.
  • The subject has any condition or is in a situation which in the investigators opinion may put the subject at significant risk, may confound study results or may interfere significantly with the subject's participation.

Cautionary Criteria:

  • The subject has any embedded electronic device that gives or receives a signal, the device should be turned off or removed prior to treatment.
  • The subject has an embedded pacemaker or implantable cardioverter defibrillator (ICD), the client's cardiologist must be consulted prior to treatment.

NOTE: This device has not been tested on patients implanted with electronic devices that receive or emit signals, such as: Pacemakers, Implantable Cardiac Defibrillators (ICD), or Cardiac Resynchronization Therapy (CRT) devices.

  • If the neutral pad would need to be placed on a subject that has a metal plate, rod, or any metal implant that could conduct heat from the Smart Handpiece or surgical handpiece.
  • The subject is allergic to adhesives, such as glues on medical tape, they should be alerted that a rash may occur on the neutral pad site and an over the counter solution may be used to treat the area.
  • If the subject has an unhealthy expectation of the results - this is not plastic surgery and all subject should be fully informed of the treatment's expected results.
  • The subject has severe laxity or sagging that causes redundant folds of tissue or hanging skin in the area to be treated - this treatment will be ineffective.
  • The subject has used Accutane (Isotretinoin) six to twelve months prior to treatment, as this can thin the skin and make it britlle
  • Studies of the use of the RF generator on subjects that have any of the following conditions is unknown:

    • Autoimmune Disease
    • Diabetic
    • Herpes Simplex
  • Use caution when treating areas that have tattoos, permanent makeup, and permanent brows.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    TempSure FlexSure Applicator

    Subjects will be treated with the TempSure FlexSure applicator device at each treatment.

    Device: Treatment with TempSure Applicator

Interventions

  • DeviceTreatment with TempSure Applicator

    Subjects will receive up to 5 treatments on the abdomen.

06

What researchers measure

Primary outcomes

  1. Correct Identification of Pre-Treatment Images Compared to Follow Up Images

    Blinded independent reviewers will be given pre-treatment and 30 day follow up images and will identify which image is pre-treatment, and which image was taken at the follow up. The percentage of correct images identified will be reported.

    Time frame: 30 Day Follow Up

  2. Correct Identification of Pre-Treatment Images Compared to Follow Up Images

    Blinded independent reviewers will be given pre-treatment and 90 day follow up images and will identify which image is pre-treatment, and which image was taken at the follow up. The percentage of correct images identified will be reported.

    Time frame: 90 Day Follow Up

07

Study locations

1 site
  • JUVA Skin & Laser Center
    New York, New York 10022, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04930705
Lead sponsor
Cynosure, Inc.
Responsible party
Sponsor
First posted
Jun 18, 2021
Start date
May 17, 2021
Primary completion
May 31, 2022
Completion
May 31, 2022
Last update
Oct 7, 2022

Study contacts

Jennifer Civiok
study director · Cynosure, Inc.

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion